Abbvie
AbbVie Inc., a global biopharmaceutical leader headquartered in the United States, was established in 2013 as a spin-off from Abbott Laboratories. With a strong presence in North America, Europe, and Asia, AbbVie focuses on developing advanced therapies in immunology, oncology, neuroscience, and virology. The company is renowned for its flagship product, Humira, which has transformed the treatment landscape for autoimmune diseases. AbbVie’s commitment to innovation is evident in its robust pipeline of biologics and small molecules, addressing unmet medical needs. Recognised for its significant contributions to healthcare, AbbVie consistently ranks among the top biopharmaceutical companies worldwide, driven by a mission to improve patient outcomes through science and research.
DitchCarbon Score
How does Abbvie's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Abbvie's score of 39 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Abbvie's reported carbon emissions
In 2023, AbbVie reported total greenhouse gas emissions of approximately 459,491,000 kg CO2e, which includes both Scope 1 and Scope 2 emissions. Specifically, Scope 1 emissions accounted for about 328,259,000 kg CO2e, while Scope 2 emissions were approximately 131,232,000 kg CO2e. AbbVie has set ambitious climate commitments, aiming for net-zero emissions across all scopes by 2050, a target established in March 2021. For the near term, AbbVie has committed to reducing its absolute Scope 1 and 2 greenhouse gas emissions by 42% by 2030, using 2021 as the baseline year. Additionally, the company plans to increase its sourcing of renewable electricity from 29.5% in 2021 to 100% by 2030. Furthermore, AbbVie aims for 79.1% of its suppliers, covering emissions from purchased goods and services, capital goods, and upstream transportation and distribution, to have science-based targets by 2027. These initiatives reflect AbbVie's commitment to sustainability and its proactive approach to addressing climate change within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 402,448,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 418,473,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Abbvie is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
